Open AccessInvasive Pneumococcal Disease Surveillance, 1 April to 30 June 2019
Author(s) -
Kate Pennington
Publication year - 2020
Publication title -
communicable diseases intelligence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.616
H-Index - 6
ISSN - 2209-6051
DOI - 10.33321/cdi.2020.44.38
Subject(s) - pneumococcal disease , serotype , pneumococcal conjugate vaccine , medicine , quarter (canadian coin) , conjugate vaccine , streptococcus pneumoniae , pediatrics , pneumococcal infections , virology , immunization , immunology , biology , microbiology and biotechnology , antibody , antibiotics , geography , archaeology
The number of notified cases of invasive pneumococcal disease (IPD) in the second quarter of 2019 was higher than the previous quarter as well as the second quarter of 2018. Following the July 2011 replacement of the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program with the 13-valent pneumococcal conjugate vaccine (13vPCV), there was an initial relatively rapid decline in disease due to the additional six serotypes covered by the 13vPCV across all age groups, however more recently this decline is no longer evident. Over this period the number of cases due to the eleven serotypes additionally covered by the 23-valent pneumococcal polysaccharide vaccine (23vPPV), and also those serotypes not covered by any available vaccine, has been increasing steadily across all age groups.